Abstract
Injecting drug use is a common mode of transmission among persons with HIV/AIDS. Many HIV-infected patients meet diagnostic criteria for opioid dependence, a chronic and relapsing brain disorder. Most HIV providers, however, receive little training in substance use disorders. Opioid agonist therapy (OAT) has a stabilizing effect on opioid-dependent patients and is associated with greater acceptance of antiretroviral (ARV) therapy, higher ARV adherence, and greater engagement in HIVrelated health care. Although methadone maintenance has been the OAT gold standard, methadone is available for the treatment of opioid dependence only in strictly regulated narcotic treatment programs. Buprenorphine, a partial opioid agonist approved for the office-based treatment of opioid dependence in 2002, may result in better health and substance use treatment outcomes for patients with HIV disease.
Similar content being viewed by others
References and Recommended Reading
Centers for Disease Control and Prevention: HIV/AIDS Surveillance Report, 2003, vol. 15. Atlanta: US Department of Health and Human Services; 2004.
San Francisco Department of Public Health: HIV/AIDS Epidemiology Annual Report, 2004. San Francisco; 2005.
Shapiro MF, Morton SC, McCaffrey DF, et al.: Variations in the care of HIV-infected adults in the United States: results from the HIV Cost and Services Utilization Study. JAMA 1999, 281:2305–2315.
Celentano DD, Vlahov D, Cohn S, et al.: Self-reported antiretroviral therapy in injection drug users. JAMA 1998, 280:544–546.
Bassetti S, Battegay M, Furrer H, et al.: Why is highly active antiretroviral therapy (HAART) not prescribed or discontinued? Swiss HIV Cohort Study. J Acquir Immune Defic Syndr 1999, 21:114–119.
Loughlin A, Metsch L, Gardner L, et al.: Provider barriers to prescribing HAART to medically-eligible HIV-infected drug users. AIDS Care 2004, 16:485–500.
Wood E, Hogg RS, Yip B, et al.: Rates of antiretroviral resistance among HIV-infected patients with and without a history of injection drug use. AIDS 2005, 19:1189–1195.
Ding L, Landon BE, Wilson IB, et al.: Predictors and consequences of negative physician attitudes toward HIV-infected injection drug users. Arch Intern Med 2005, 165:618–623.
Miller NS, Sheppard LM, Colenda CC, Magen J: Why physicians are unprepared to treat patients who have alcohol-and drug-related disorders. Acad Med 2001, 76:410 -418.
Fleming M, Barry K, Davis A, et al.: Medical education about substance abuse: changes in curriculum and faculty between 1976 and 1992. Acad Med 1994, 69:362–369.
Merrill JO, Rhodes LA, Deyo RA, et al.: Mutual mistrust in the medical care of drug users: the keys to the "narc" cabinet. J Gen Intern Med 2002, 17:327–333.
Saitz R, Friedmann PD, Sullivan LM, et al.: Professional satisfaction experienced when caring for substance-abusing patients: faculty and resident physician perspectives. J Gen Intern Med 2002, 17:373–376.
Kreek MJ, Bart G, Lilly C, et al.: Pharmacogenetics and human molecular genetics of opiate and cocaine addictions and their treatments. Pharmacol Rev 2005, 57:1–26. Detailed and thorough review of the genetic basis of opiate and cocaine use and their treatments.
de Ridder M: Heroin: new facts about an old myth. J Psychoactive Drugs 1994, 26:65–68.
Jaffe JH, O‘Keeffe C: From morphine clinics to buprenorphine: regulating opioid agonist treatment of addiction in the United States. Drug Alcohol Depend 2003, 70:S3-S11.
Ciccarone D, Bourgois P: Explaining the geographical variation of HIV among injection drug users in the United States. Subst Use Misuse 2003, 38:2049–2063.
Passaro DJ, Werner SB, McGee J, et al.: Wound botulism associated with black tar heroin among injecting drug users. JAMA 1998, 279:859–863.
Substance Abuse and Mental Health Services Administration: Overview of findings from the 2003 National Survey on Drug Use and Health. In NSDUH Series H-24, DHHS Publication No SMA 04-3963. Rockville, MD: US Department of Health and Human Services; 2004.
Compton WM, Volkow ND: Major increases in opioid analgesic abuse in the United States: Concerns and strategies. Drug Alcohol Depend 2006, 81:103–107.
Substance Abuse and Mental Health Services Administration: Nonmedical oxycodone users: a comparison with heroin users. In The National Survey on Drug Use and Health. Rockville, MD: US Department of Health and Human Services; 2005.
Effective medical treatment of opiate addiction. National Consensus Development Panel on Effective Medical Treatment of Opiate Addiction. JAMA 1998, 280:1936–1943.
Stimmel B, Kreek MJ: Neurobiology of addictive behaviors and its relationship to methadone maintenance. Mt Sinai J Med 2000, 67:375–380.
Kreek MJ, Nielsen DA, Butelman ER, LaForge KS: Genetic influences on impulsivity, risk taking, stress responsivity and vulnerability to drug abuse and addiction. Nat Neurosci 2005, 8:1450–1457.
McLellan AT, Lewis DC, O‘Brien CP, Kleber HD: Drug dependence, a chronic medical illness: implications for treatment, insurance, and outcomes evaluation. JAMA 2000, 284:1689–1695.
Nestler EJ, Aghajanian GK: Molecular and cellular basis of addiction. Science 1997, 278:58–63.
Koob GF, Sanna PP, Bloom FE: Neuroscience of addiction. Neuron 1998, 21:467–476.
Kreek MJ, Koob GF: Drug dependence: stress and dysregulation of brain reward pathways. Drug Alcohol Depend 1998, 51:23–47.
Sulkowski MS, Thomas DL: Hepatitis C in the HIVinfected person. Ann Intern Med 2003, 138:197–207.
Perlman DC, Salomon N, Perkins MP, et al.: Tuberculosis in drug users. Clin Infect Dis 1995, 21:1253.
Boschini A, Smacchia C, Di Fine M, et al.: Communityacquired pneumonia in a cohort of former injection drug users with and without human immunodeficiency virus infection: incidence, etiologies, and clinical aspects. Clin Infect Dis 1996, 23:107–113.
Gordon RJ, Lowy FD: Bacterial infections in drug users. N Engl J Med 2005, 353:1945–1954.
Hulse GK, English DR, Milne E, Holman CDJ: The quantification of mortality resulting from the regular use of illicit opiates. Addiction 1999, 94:221–229.
Substance Abuse and Mental Health Services Administration: Emergency department trends from the Drug Abuse Warning Network, final estimates 1995–2002. In DAWN Series: D-24, DHHS Publication No (SMA) 03-3780. Rockville, MD: US Department of Health and Human Services; 2003.
Substance Abuse and Mental Health Services Administration: Drug Abuse Warning Network, 2003: area profiles of drug-related mortality. In DAWN Series D-27, DHHS Publication No (SMA) 05-4023. Rockville, MD: US Department of Health and Human Services; 2005.
Gossop M, Stewart D, Treacy S, Marsden J: A prospective study of mortality among drug misusers during a 4-year period after seeking treatment. Addiction 2002, 97:39–47.
Degenhardt L, Hall W, Warner-Smith M: Using cohort studies to estimate mortality among injecting drug users that is not attributable to AIDS. Sex Transm Infect 2006, 82:iii56–63.
Sporer KA: Acute heroin overdose. Ann Intern Med 1999, 130:584–590.
Wang C, Vlahov D, Galai N, et al.: The effect of HIV infection on overdose mortality. AIDS 2005, 19:935–942.
Krantz MJ, Mehler PS: Treating opioid dependence. Growing implications for primary care. Arch Intern Med 2004, 164:277–288.
Ball J, Corty E, Bond H, Myers C, Tommasello A: The reduction of intravenous heroin use, non-opiate abuse and crime during methadone maintenance treatment: further findings. NIDA Res Monogr 1988, 81:224–230.
Caplehorn JR, Ross MW: Methadone maintenance and the likelihood of risky needle-sharing. Int J Addict 1995, 30:685–698.
Gibson DR, Flynn NM, McCarthy JJ: Effectiveness of methadone treatment in reducing HIV risk behavior and HIV seroconversion among injecting drug users. AIDS 1999, 13:1807–1818.
Moss AR, Vranizan K, Gorter R, et al.: HIV seroconversion in intravenous drug users in San Francisco, 1985–1990. AIDS 1994, 8:223–231.
Metzger DS, Woody GE, McLellan AT, et al.: Human immunodeficiency virus seroconversion among intravenous drug users in-and out-of-treatment: an 18-month prospective follow-up. J Acquir Immune Defic Syndr 1993, 6:1049–1056.
Gossop M, Trakada K, Stewart D, Witton J: Reductions in criminal convictions after addiction treatment: 5-year follow-up. Drug Alcohol Depend 2005, 79:295–302.
Brugal MT, Domingo-Salvany A, Puig R, Barrio G, et al.: Evaluating the impact of methadone maintenance programmes on mortality due to overdose and aids in a cohort of heroin users in Spain. Addiction 2005, 100:981–989.
Weber R, Ledergerber B, Opravil M, et al.: Progression of HIV infection in misusers of injected drugs who stop injecting or follow a programme of maintenance treatment with methadone. BMJ 1990, 301:1362–1365.
Laine C, Hauck WW, Turner BJ: Outpatient patterns of care and longitudinal intensity of antiretroviral therapy for HIV-infected drug users. Med Care 2002, 40:976–995.
Laine C, Hauck WW, Gourevitch MN, et al.: Regular outpatient medical and drug abuse care and subsequent hospitalization of persons who use illicit drugs. JAMA 2001, 285:2355–2362.
Fiellin DA, O‘Connor PG: New federal initiatives to enhance the medical treatment of opioid dependence. Ann Intern Med 2002, 137:688–692.
Jasinski DR, Pevnick JS, Griffith JD: Human pharmacology and abuse potential of the analgesic buprenorphine: a potential agent for treating narcotic addiction. Arch Gen Psychiatry 1978, 35:501–516.
Bickel WK, Stitzer ML, Bigelow GE, et al.: Buprenorphine: dose-related blockade of opioid challenge effects in opioid dependent humans. J Pharmacol Exp Ther 1988, 247:47–53.
Chiang CN, Hawks RL: Pharmacokinetics of the combination tablet of buprenorphine and naloxone. Drug Alcohol Depend 2003, 70:S39-S47.
Marsch LA, Bickel WK, Badger GJ, Jacobs EA: Buprenorphine treatment for opioid dependence: the relative efficacy of daily, twice and thrice weekly dosing. Drug Alcohol Depend 2005, 77:195–204.
Lange WR, Fudala PJ, Dax EM, Johnson RE: Safety and side-effects of buprenorphine in the clinical management of heroin addiction. Drug Alcohol Depend 1990, 26:19–28.
Petry NM, Bickel WK, Piasecki D, et al.: Elevated liver enzyme levels in opioid-dependent patients with hepatitis treated with buprenorphine. Am J Addict 2000, 9:265–269.
Berson A, Gervais A, Cazals D, et al.: Hepatitis after intravenous buprenorphine misuse in heroin addicts. J Hepatol 2001, 34:346–350.
Herve S, Riachi G, Noblet C, et al.: Acute hepatitis due to buprenorphine administration. Eur J Gastroenterol Hepatol 2004, 16:1033–1037.
Johnson RE, Jones HE, Jasinski DR, et al.: Buprenorphine treatment of pregnant opioid-dependent women: maternal and neonatal outcomes. Drug Alcohol Depend 2001, 63:97–103.
Jones HE, Johnson RE, Jasinski DR, et al.: Buprenorphine versus methadone in the treatment of pregnant opioiddependent patients: effects on the neonatal abstinence syndrome. Drug Alcohol Depend 2005, 79:1–10.
Cowan A, Doxey JC, Harry EJ: The animal pharmacology of buprenorphine, an oripavine analgesic agent. Br J Pharmacol 1977, 60:547–554.
Sporer KA: Buprenorphine: a primer for emergency physicians. Ann Emerg Med 2004, 43:580–584.
Auriacombe M, Franques P, Tignol J: Deaths attributable to methadone vs buprenorphine in France. JAMA 2001, 285:45.
Reynaud M, Petit G, Potard D, Courty P: Six deaths linked to concomitant use of buprenorphine and benzodiazepines. Addiction 1998, 93:1385–1392.
Tracqui A, Kintz P, Ludes B: Buprenorphine-related deaths among drug addicts in France: a report on 20 fatalities. J Anal Toxicol 1998, 22:430–434.
Stoller KB, Bigelow GE, Walsh SL, Strain EC: Effects of buprenorphine/naloxone in opioid-dependent humans. Psychopharmacology 2001, 154:230.
Johnson RE, Eissenberg T, Stitzer ML, et al.: A placebo controlled clinical trial of buprenorphine as a treatment for opioid dependence. Drug Alcohol Depend 1995, 40:17–25.
Krook AL, Brors O, Dahlberg J, et al.: A placebo-controlled study of high dose buprenorphine in opiate dependents waiting for medication-assisted rehabilitation in Oslo, Norway. Addiction 2002, 97:533–542.
Johnson RE, Jaffe JH, Fudala PJ: A controlled trial of buprenorphine treatment for opioid dependence. JAMA 1992, 267:2750–2755.
Johnson RE, Chutuape MA, Strain EC, et al.: A comparison of levomethadyl acetate, buprenorphine, and methadone for opioid dependence. N Engl J Med 2000, 343:1290 -1297.
Barnett PG, Zaric GS, Brandeau ML: The cost-effectiveness of buprenorphine maintenance therapy for opiate addiction in the United States. Addiction 2001, 96:1267–1278.
O‘Connor PG, Oliveto AH, Shi JM, et al.: A randomized trial of buprenorphine maintenance for heroin dependence in a primary care clinic for substance users versus a methadone clinic. Am J Med 1998, 105:100–105.
Fudala PJ, Bridge TP, Herbert S, et al.: Office-based treatment of opiate addiction with a sublingual-tablet formulation of buprenorphine and naloxone. N Engl J Med 2003, 349:949–958.
Herget G: Methadone and buprenorphine added to the WHO list of essential medicines. HIV AIDS Policy Law Rev 2005, 10:23–24.
Moatti JP, Carrieri MP, Spire B, et al.: Adherence to HAART in French HIV-infected injecting drug users: the contribution of buprenorphine drug maintenance treatment. The Manif 2000 study group. AIDS 2000, 14:151–155.
Carrieri MP, Rey D, Loundou A, et al.: Evaluation of buprenorphine maintenance treatment in a French cohort of HIV-infected injecting drug users. Drug Alcohol Depend 2003, 72:13–21.
Carrieri MP, Vlahov D, Dellamonica P, et al.: Use of buprenorphine in HIV-infected injection drug users: negligible impact on virologic response to HAART. The Manif-2000 Study Group. Drug Alcohol Depend 2000, 60:51–54.
Basu S, Smith-Rohrberg D, Bruce RD, Altice FL: Models for integrating buprenorphine therapy into the primary HIV care setting. Clin Infect Dis 2006, 42:716–721. eview of the advantages and disadvantages of four models that may be used to integrate buprenorphine into HIV primary care settings.
Verster A, Buning E: Buprenorphine: Critical Questions Answered. Amsterdam: Quest for Quality BV; 2005.
Lintzeris N, Clark N, Winstock A, et al.: National Clinical Guidelines and Procedures for the Use of Buprenorphine in the Treatment of Opioid Dependence. Intergovernmental Committee on Drugs (IGCD) subcommittee MaOT ed. Canberra: Australian Department of Health and Ageing; 2006. Recently revised and well-written clinical guidelines for the safe and effective provision of buprenorphine treatment in Australia but with significant relevance for practitioners worldwide.
Center for Substance Abuse Treatment: Clinical Guidelines for the Use of Buprenorphine in the Treatment of Opioid Addiction. Treatment Improvement Protocol (TIP) Series 40. DHHS Publication No. (SMA) 04-3939. Substance Abuse and Mental Health Services Administration: Rockville, MD; 2004.
Wesson DR, Ling W: The clinical opiate withdrawal scale (COWS). J Psychoactive Drugs 2003, 35:253–259.
Fiellin DA, Kleber H, Trumble-Hejduk JG, et al.: Consensus statement on office-based treatment of opioid dependence using buprenorphine. J Subst Abuse Treat 2004, 27:153.
Amass L, Bickel WK, Crean JP, et al.: Alternate-day buprenorphine dosing is preferred to daily dosing by opioid-dependent humans. Psychopharmacology (Berl) 1998, 136:217–225.
Fiellin DA, Pantalon MV, Chawarski MC, et al.: Counseling plus buprenorphine-naloxone maintenance therapy for opioid dependence. N Engl J Med 2006, 355:365–374.
Baker JR, Best AM, Pade PA, McCance-Katz EF: Effect of buprenorphine and antiretroviral agents on the QT interval in opioid-dependent patients. Ann Pharmacother 2006, 40:392–396.
Bruce RD, Altice FL, Gourevitch MN, Friedland GH: Pharmacokinetic drug interactions between opioid agonist therapy and antiretroviral medications: implications and management for clinical practice. J Acquir Immune Defic Syndr 2006, 41:563–572. A review of the literature describing the pharmacokinetic interaction between ARVs and opioid agonist therapies, including methadone and buprenorphine.
McCance-Katz EF, Rainey PM, Friedland G, et al.: Effect of opioid dependence pharmacotherapies on zidovudine disposition. Am J Addict 2001, 10:296–307.
McCance-Katz EF, Pade PA, Friedland G, et al.: Efavirenz decreases buprenorphine exposure, but is not associated with opiate withdrawal in opioid dependent individuals [abstract]. In Program and Abstracts of the 12th Conference on Retroviruses and Opportunistic Infections. Boston, MA; February 22–25, 2005.
Iribarne C, Berthou F, Carlhant D, et al.: Inhibition of methadone and buprenorphine N-dealkylations by three HIV-1 protease inhibitors. Drug Metab Dispos 1998, 26:257–260.
Iribarne C, Picart D, Dreano Y, et al.: Involvement of cytochrome P450 3A4 in N-dealkylation of buprenorphine in human liver microsomes. Life Sci 1997, 60:1953–1964.
Decker CJ, Laitinen LM, Bridson GW, et al.: Metabolism of amprenavir in liver microsomes: role of CYP3A4 inhibition for drug interactions. J Pharm Sci 1998, 87:803–807.
Alford DP, Compton P, Samet JH: Acute pain management for patients receiving maintenance methadone or buprenorphine therapy. Ann Intern Med 2006, 144:127–134. This perspective addresses common misconceptions by providers in managing acute pain in patients receiving opiod agonist therapy and represents a useful, standardized approach to managing acute pain in this setting.
Breitbart W, Rosenfeld BD, Passik SD, et al.: The undertreatment of pain in ambulatory AIDS patients. Pain 1996, 65:243–249.
Olsen Y, Alford DP: Chronic pain management in patients with substance use disorders. Adv Stud Med 2006, 6:111–123.
Malinoff HL, Barkin RL, Wilson G: Sublingual buprenorphine is effective in the treatment of chronic pain syndrome. Am J Ther 2005, 12:379–384.
Merrill JO: Integrating medical care and addiction treatment. J Gen Intern Med 2003, 18:68–69.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Lum, P.J., Tulsky, J.P. The medical management of opioid dependence in HIV primary care settings. Curr HIV/AIDS Rep 3, 195–204 (2006). https://doi.org/10.1007/s11904-006-0016-z
Issue Date:
DOI: https://doi.org/10.1007/s11904-006-0016-z